Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3
Annals of Neurology · 2026
DOI: 10.1002/ana.78317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, 2026. Verfasst von Juan P Mato und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Michigan, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Ataxin-3, Sensory Receptor Cells, Peripheral Nervous System Diseases, Peptides. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Objective
Repeat expansion mutations underlie diverse neurogenetic disorders, many involving the peripheral nervous system. Despite peripheral neuropathy being the most common neurological disorder worldwide, its contribution to repeat expansion diseases remains poorly defined, and robust preclinical models are limited. We established a translational framework to study peripheral neuropathy in spinocerebellar ataxia type 3 (SCA3), a fatal multisystem disorder caused by a pathogenic CAG expansion in ATXN3.
Methods
SCA3 Knock‐In Atxn3 Q300/Q6 (KI) and Atxn3 −/− Knock‐Out (KO) mice underwent sensorimotor nerve conduction and behavioral testing. Peripheral tissues were evaluated for SCA3‐related pathology, and transcriptional changes in KI dorsal root ganglia (DRG) were assessed by bulk RNA sequencing. To test therapeutic relevance, we generated a conditional “OFF” SCA3 knock‐in (cKI) mouse and crossed it with Avil‐Cre to selectively silence mutant ATXN3 in sensory neurons. Peripheral phenotyping was repeated in Avil‐Cre; cKI mice.
Results
KI mice developed progressive sensorimotor deficits, peripheral histopathology, and RNA splicing dysregulation that parallel clinical features of SCA3. In contrast, KO mice showed normal peripheral nerve function, implicating toxic gain‐of‐function from mutant ATXN3 as the causative driver. Sensory neuron–specific silencing of mutant ATXN3 significantly ameliorated peripheral nerve abnormalities and DRG splicing dysregulation.
Interpretation
These findings define a pathogenic role for repeat expansion–driven peripheral nerve degeneration in SCA3, identify sensory neurons as key therapeutic targets, and provide a preclinical platform for developing peripheral interventions in SCA3 and related repeat expansion disorders. ANN NEUROL 2026;100:1039–1054
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
- Neuroscience Graduate Program, University of Michigan, Ann Arbor, MI, USA.
- Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA.
ORCID-Profile: Jacen Emerson, Alexandra F Putka, Hayley S McLoughlin
Förderung
- NINDS NIH HHS
Zitieren
APA
Mato, J. P., Hayes, J. M., Emerson, J., Sridharan, M., Adelaja, T., Naeem, A., Putka, A. F., & McLoughlin, H. S. (2026). Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3. Annals of Neurology. https://doi.org/10.1002/ana.78317
Vancouver
Mato JP, Hayes JM, Emerson J, Sridharan M, Adelaja T, Naeem A, et al. Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3. Annals of Neurology. 2026. doi:10.1002/ana.78317
BibTeX
@article{Mato2026,
author = {Mato, Juan P and Hayes, John M and Emerson, Jacen and Sridharan, Maeha and Adelaja, Toluwani and Naeem, Arsal and Putka, Alexandra F and McLoughlin, Hayley S},
title = {Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3},
journal = {Annals of Neurology},
year = {2026},
doi = {10.1002/ana.78317}
}
EUVIMED